Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01767415 · ClinicalTrials.gov registry record · Phase 1

Intra-operative Use of Indigo Carmine Dye for the Delineation of Ill Defined Tumor Borders Using Stereotactic Injection

A Phase 1 study, sponsored by Weill Medical College of Cornell University.

Completed
Registry status
Phase 1
Development phase
10
Enrollment target

NCT01767415 is a Phase 1 study that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 10 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01767415, a Phase 1 study, has completed, sponsored by Weill Medical College of Cornell University.

COMPLETED
Registry status
Phase 1
Development phase
10 participants
Enrollment target

Study Summary

The purpose of this study is to investigate whether stereotactic indigo carmine injection can safely increase the extent of tumor resection.

Interventions

  • DRUG Indigo carmine

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2012-04
Est. Completion 2014-09
Phase Phase 1

What the Registry Record Tells You About NCT01767415

The ClinicalTrials.gov registry entry for NCT01767415 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Indigo carmine is the first listed.

NCT01767415 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01767415 about?

NCT01767415 is a clinical study titled "Intra-operative Use of Indigo Carmine Dye for the Delineation of Ill Defined Tumor Borders Using Stereotactic Injection". The purpose of this study is to investigate whether stereotactic indigo carmine injection can safely increase the extent of tumor resection.

What is the current status of trial NCT01767415?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2012-04. Estimated completion is 2014-09.

What interventions are being tested in trial NCT01767415?

The interventions under investigation include: Indigo carmine (DRUG).

Who is sponsoring clinical trial NCT01767415?

This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.